• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus-Positive Screening Test Results.病因性共病因素对 HPV 阳性筛查试验结果女性中 CIN3+风险的贡献。
J Low Genit Tract Dis. 2022 Apr 1;26(2):127-134. doi: 10.1097/LGT.0000000000000667.
2
The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.英格兰原发性人乳头瘤病毒子宫颈筛查的临床效果和成本效益:通过三轮筛查对 ARTISTIC 随机试验队列进行的扩展随访。
Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.
3
HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.HPV 检测与常规细胞学检查在宫颈癌筛查中的比较:ARTISTIC RCT 的长期随访。
Health Technol Assess. 2019 Jun;23(28):1-44. doi: 10.3310/hta23280.
4
Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.在随机环境中对原发性人乳头瘤病毒筛查与传统细胞学进行特定年龄评估。
J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.
5
Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.以人乳头瘤病毒检测为基础的宫颈癌筛查间隔时间的延长:英国筛查试点数据的观察性研究。
BMJ. 2022 May 31;377:e068776. doi: 10.1136/bmj-2021-068776.
6
The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.特定型别人乳头瘤病毒感染对宫颈癌前病变和癌症检出的影响:美国机会性宫颈筛查的基于人群研究。
Int J Cancer. 2014 Aug 1;135(3):624-34. doi: 10.1002/ijc.28605. Epub 2014 Apr 15.
7
Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.人乳头瘤病毒阴性意义不明确的非典型鳞状细胞女性的癌前病变风险及随访管理策略
Obstet Gynecol. 2007 Jun;109(6):1325-31. doi: 10.1097/01.AOG.0000263461.71732.40.
8
Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.HPV 检测结果为 ASC-US 的女性中,CIN3+和宫颈癌的 5 年风险。
J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S36-42. doi: 10.1097/LGT.0b013e3182854253.
9
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.25 岁及以上女性宫颈癌筛查中致癌型人乳头瘤病毒(HPV)检测及 HPV16 或 HPV18 基因分型的性能:ATHENA 研究的一项亚组分析。
Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.
10
Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.阴道镜检查后的随访检测:阴道镜检查诊断为 CIN1 及以下病变后 5 年的 CIN2+风险。
J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S69-77. doi: 10.1097/LGT.0b013e31828543b1.

引用本文的文献

1
Advances in cervical cancer: current insights and future directions.宫颈癌的进展:当前见解与未来方向
Cancer Commun (Lond). 2025 Feb;45(2):77-109. doi: 10.1002/cac2.12629. Epub 2024 Nov 29.
2
Nationwide study on development and validation of a risk prediction model for CIN3+ and cervical cancer in Estonia.一项针对爱沙尼亚 CIN3+ 和宫颈癌风险预测模型的开发和验证的全国性研究。
Sci Rep. 2024 Oct 19;14(1):24589. doi: 10.1038/s41598-024-75697-3.
3
Public health concern-driven insights and response of low- and middle-income nations to the World health Organization call for cervical cancer risk eradication.低收入和中等收入国家基于公共卫生关切的见解以及对世界卫生组织消除宫颈癌风险呼吁的回应。
Gynecol Oncol Rep. 2024 Jul 14;54:101460. doi: 10.1016/j.gore.2024.101460. eCollection 2024 Aug.
4
Design of the HPV-automated visual evaluation (PAVE) study: Validating a novel cervical screening strategy.HPV 自动化视觉评估(PAVE)研究设计:验证一种新的宫颈癌筛查策略。
Elife. 2024 Jan 15;12:RP91469. doi: 10.7554/eLife.91469.

病因性共病因素对 HPV 阳性筛查试验结果女性中 CIN3+风险的贡献。

Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus-Positive Screening Test Results.

机构信息

Division of Cancer Epidemiology and Genetics and Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.

University of California, Los Angeles, CA.

出版信息

J Low Genit Tract Dis. 2022 Apr 1;26(2):127-134. doi: 10.1097/LGT.0000000000000667.

DOI:10.1097/LGT.0000000000000667
PMID:35249974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8940696/
Abstract

OBJECTIVE

The US screening and management guidelines for cervical cancer are based on the absolute risk of precancer estimated from large clinical cohorts and trials. Given the widespread transition toward screening with human papillomavirus (HPV) testing, it is important to assess which additional factors to include in clinical risk assessment to optimize management of HPV-infected women.

MATERIALS AND METHODS

We analyzed data from HPV-infected women, ages 30-65 years, in the National Cancer Institute-Kaiser Permanente Northern California Persistence and Progression study. We estimated the influence of HPV risk group, cytology result, and selected cofactors on immediate risk of cervical intraepithelial neoplasia grade 3 or higher (CIN 3+) among 16,094 HPV-positive women. Cofactors considered included, age, race/ethnicity, income, smoking, and hormonal contraceptive use.

RESULTS

Human papillomavirus risk group and cytology test result were strongly correlated with CIN 3+ risk. After considering cytology and HPV risk group, other cofactors (age, race/ethnicity, income, smoking, and hormonal contraceptive use) had minimal impact on CIN 3+ risk and did not change recommended management based on accepted risk thresholds. We had insufficient data to assess the impact of long-duration heavy smoking, parity, history of sexually transmitted infection, or immunosuppression.

CONCLUSIONS

In our study at the Kaiser Permanente Northern California, the risk of CIN 3+ was determined mainly by HPV risk group and cytology results, with other cofactors having limited impact in adjusted analyses. This supports the use of HPV and cytology results in risk-based management guidelines.

摘要

目的

美国的宫颈癌筛查和管理指南是基于从大型临床队列和试验中估计的癌前病变的绝对风险。鉴于广泛向人乳头瘤病毒(HPV)检测筛查转变,评估在临床风险评估中纳入哪些额外因素以优化 HPV 感染女性的管理非常重要。

材料和方法

我们分析了美国国家癌症研究所-凯撒永久北加利福尼亚持续和进展研究中年龄在 30-65 岁之间的 HPV 感染女性的数据。我们估计了 HPV 风险组、细胞学结果和选定的协变量对 16094 名 HPV 阳性女性中即刻发生宫颈上皮内瘤变 3 级或更高(CIN3+)的影响。考虑的协变量包括年龄、种族/族裔、收入、吸烟和激素避孕使用。

结果

HPV 风险组和细胞学检测结果与 CIN3+风险密切相关。在考虑细胞学和 HPV 风险组后,其他协变量(年龄、种族/族裔、收入、吸烟和激素避孕使用)对 CIN3+风险的影响很小,并且不会根据接受的风险阈值改变推荐的管理。我们的数据不足以评估长期大量吸烟、产次、性传播感染史或免疫抑制的影响。

结论

在我们对 Kaiser Permanente Northern California 的研究中,CIN3+的风险主要由 HPV 风险组和细胞学结果决定,在调整分析中其他协变量的影响有限。这支持在基于风险的管理指南中使用 HPV 和细胞学结果。